Menu
← Oncology Approval Tracker
FDA DECISION ·
Inlexzo
gemcitabine intravesical system · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with BCG-unresponsive non-muscle-invasive bladder cancer and carcinoma in situ, with or without papillary tumors.
LAMPGEN ANALYSIS
Why it matters
The drug-containing system delivers sustained gemcitabine within the bladder for eligible patients with BCG-unresponsive disease.
What research teams should watch
Train urology staff on placement, scheduled removal, and safety precautions; keep cystoscopic surveillance and cystectomy referral on schedule.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
BCG-unresponsive non-muscle-invasive bladder cancerPRIMARY RECORDS